2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 352

Remaining Pain in Spite of Suppressed Inflammation in Early Rheumatoid Arthritis – Long-Term Strongly Increased Risk for Widespread Pain and Fatigue
Abstract Number: L15

Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
Abstract Number: 474

Renacer Study: Assessment of 12-Month Efficacy and Safety of 168 Certolizumabpegol Rheumatoid Arthritis Treated Patients from a Multicenter Retrospective National Study in Spain
Abstract Number: 2549

Renal Involvement in Primary Sjögren’s Syndrome: A Multicenter French Study of 95 Biopsy Proven Cases
Abstract Number: 1671

Renal Relapses Are Common in Lupus Nephritis
Abstract Number: 1658

Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes
Abstract Number: 2086

Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 1188

Reproducibility of Magnetic Resonance Imaging Diffusion Weighted Imaging in Axial Spondyloarthritis Patients and Healthy Subjects
Abstract Number: 1992

Resident’s Guide to Rheumatology Mobile Application: An International Needs Assessment
Abstract Number: 2975

Residual Large Joint Synovitis By Power Doppler Ultrasonography Is Associated with Higher Disease Activity and Significant Impact of Disease in Multi-Ethnic Asian Patients with Established Rheumatoid Arthritis
Abstract Number: 1588

Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life
Abstract Number: 105

Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Abstract Number: 2038

Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sIL-2Rá): Results of a 21-Year Community-Based Cohort Survival Analysis
Abstract Number: 1482

Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)
Abstract Number: 931

Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].